Table 2.
Cumulative incidence of study outcomes by time period
| Outcome | All | Time Period | P-value for trend | |||||
|---|---|---|---|---|---|---|---|---|
| 85–89 | 90–94 | 95–99 | 00–04 | 05–09 | ||||
| ESRD-free survival | 1-year | 75% | 73% | 72% | 66% | 82% | 82% | 0.02 | 
| 3-year | 61% | 51% | 57% | 53% | 69% | 72% | < 0.001 | |
| 5-year | 54% | 39% | 53% | 40% | 68% | 70% | < 0.001 | |
|  | ||||||||
| Patient survival | 1-year | 91% | 89% | 89% | 89% | 93% | 90% | 0.36 | 
| 3-year | 81% | 74% | 84% | 73% | 87% | 83% | 0.15 | |
| 5-year | 72% | 64% | 71% | 58% | 84% | 83% | < 0.001 | |
|  | ||||||||
| Renal survival | 1-year | 80% | 77% | 77% | 70% | 86% | 89% | 0.005 | 
| 3-year | 69% | 60% | 61% | 60% | 76% | 84% | < 0.001 | |
| 5-year | 65% | 51% | 61% | 53% | 76% | 82% | < 0.001 | |
|  | ||||||||
| Relapse | 1-year | 11% | 5% | 7% | 12% | 14% | 15% | 0.008 | 
| 3-year | 29% | 22% | 25% | 28% | 28% | 40% | 0.01 | |
| 5-year | 35% | 28% | 27% | 33% | 30% | 57% | < 0.001 | |
ESRD, end-stage renal disease